Condition: HIV Infections · Breast Cancer · Pediatric Emergency Medicine · Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
This research is a continuation of a usability study with the MARVIN chatbot. The investigators aim to adapt the MARVIN chatbot to open it to other health domains (e.g. breast cancer) and populations (e.g. pharmacists). Therefore, this protocol constitutes a master research protocol that will englobe different research projects with individual chatbots. The investigators adopt an adaptive platform trial design, which will allow flexibility in handling multiple interventions adapted to different populations while retaining the characteristics of a platform trial design allowing early withdrawal of ineffective trial arms based on interim data (implementation outcomes) and introduction of new trial arms.
This description comes directly from the study's public registry record.
Bertrand Lebouché, MD · 514-843-2090 · bertrand.lebouche@mcgill.ca
Always discuss trial participation with your own doctor first.
| Centre hospitalier de l'Université de Montréal (CHUM) | Montreal, Quebec, Canada | Recruiting |
| McGill University Health Centre (MUHC) | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05789901